Renaissance Capital logo

Aardvark Therapeutics Priced, Nasdaq: AARD

Phase 3 biotech developing novel small molecule therapies for metabolic diseases.

Industry: Health Care

Latest Trade: $13.74 0.00 (0.0%)

First Day Return: -10.6%

Return from IPO: -14.1%

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients. We have focused our efforts on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Our initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Our research has shown that activating these receptors can induce secretion of endogenous signaling molecules, including cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1). Our wholly-owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which we have initiated a Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS). We also intend to evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation (HO). In our completed Phase 2 clinical trial in subjects with hyperphagia associated with PWS, ARD-101 was shown to be well-tolerated and demonstrated clinical activity through a reduction in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score. We have aligned with the U.S. Food and Drug Administration (the FDA) on a protocol for a potentially pivotal Phase 3 clinical trial, which we initiated in December 2024, and we anticipate topline data will be available in early 2026.
IPO Data
IPO Date 02/12/2025
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 5.9
Deal Size ($mm) $94
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
BofA Securities
more
Company Data
Headquarters San Diego, CA, United States
Founded 2017
Employees at IPO 18
Website aardvarktherapeutics.com

Aardvark Therapeutics (AARD) Performance

Created with Highcharts 10.3.2Chart context menuAARD vs. IPO Index (IPOUSA)12. Feb13. Feb14. Feb16. Feb18. Feb19. Feb20. Feb21. Feb-20%-10%0%+ 10%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexAARDOur ETF tracks the IPO Index